Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander
1 other identifier
interventional
124
0 countries
N/A
Brief Summary
The experimental hypothesis of this randomized controlled study was to demonstrate that early drain removal in patients who underwent immediate breast reconstruction with tissue expander is a safety procedure to improving clinical outcomes and quality of life (QoL). The mechanism of action underlying the proposed approach was intuitive. The early drain removal allows to: 1) avoid continuous seroma development caused by active suction of drain (stopping the circle "drain itself may perpetuate the drainage" with vacuum mechanism); 2) reduce the risks connected to "foreign body reaction" as tissue inflammation and infection; 3) improve QoL reducing pain, length of hospital stay and limitations of daily activities.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2016
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2018
CompletedFirst Submitted
Initial submission to the registry
November 28, 2019
CompletedFirst Posted
Study publicly available on registry
December 6, 2019
CompletedDecember 10, 2019
December 1, 2019
1.6 years
November 28, 2019
December 6, 2019
Conditions
Outcome Measures
Primary Outcomes (6)
total fluid volume (ml)
sum of drain volumes and volume of seroma aspirations if needed
21 days
days with drainage
21 days
days of seroma formation
period that drain or seroma aspiration is needed in days after surgery
21 days
time until wound healing (days)
21 days
infection (yes or not)
defined as the appearance of local signs/symptoms as erythema, edema, induration, increased pain, and a change in drainage to a purulent nature and fever, confirmed by swabs
21 days
complicated wound healing (yes or not)
unclosed wound 3 weeks postoperatively
21 days
Secondary Outcomes (4)
pain (using Visual Analogic Score scale to measure intensity)
21 days
disturbance in quality of sleep (yes or not)
21 days
limitation in personal care, daily activities and social life (yes or not)
21 days
disturbance in mobility (yes or not)
21 days
Study Arms (2)
output based group
ACTIVE COMPARATORInvestigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days with no further signs of infection, fluid collection or impaired wound healing
early-removal group
EXPERIMENTALInvestigators remove the drains at hospital discharge, 3-4 days after surgery, regardless of the output at that time
Interventions
Investigators remove the drains when the suction drain flow was less than 30 ml/day for at least 2 days or at discharge, with no further signs of infection, fluid collection or impaired wound healing ("complicated", see below). Ultimately, we removed drains 3 weeks postoperatively (21 days post op) even if the flow was higher than 30 ml/day. However, leakage or severe patient discomfort led to immediate drain removal at any time during postoperative care.
Eligibility Criteria
You may qualify if:
- SNS (skin nipple sparing) or SS (skin sparing) mastectomy for breast cancer and immediate positioning of breast expander (without mesh) with placement of suction drain, regardless of TNM classification
You may not qualify if:
- skin reducing mastectomy, reconstruction with flap, direct to implant reconstruction (with or without mesh or ADM) and axillary dissection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 28, 2019
First Posted
December 6, 2019
Study Start
September 1, 2016
Primary Completion
March 31, 2018
Study Completion
December 31, 2018
Last Updated
December 10, 2019
Record last verified: 2019-12